Partners Healthcare and Medison Pharma-backed Keros Therapeutics floated at the top of its range and will look to advance its musculoskeletal disorder drug candidates.
Naver, Simon Property and O’Reilly Media-backed Foursquare is joining forces with peer Factual to create the world's biggest location intelligence provider.
Novo and Takeda are set to exit antibody therapy developer Symphogen in an acquisition by one of its strategic partners, Servier.
The Pharamron-backed oncology drug developer floated at the top of its range while increasing the number of shares in the offering.
NetEase, SoftBank, Time Warner, Madison Square Garden, Dick Clark Productions, Citic Guoan, Founder Group and Comcast could all exit the virtual event platform developer.
Invesco will sell its unquoted UK holdings to reallocate its capital to public stocks, meaning disruption for numerous spinouts and Oxford Sciences Innovation.
Mozido, Sberbank and Overstock all scored exits as the e-commerce verification software developer was bought for an undisclosed amount.
Intel Capital is exiting SD-WAN software provider CloudGenix in an acquisition that follows $99m in funding across three rounds.
A stake of up to $100m in Gojek has reportedly been offered to secondary market buyers while a corporate is also looking to sell stock in fellow ride hailing platform Didi Chuxing.
The Microsoft subsidiary backed AnyVision's $74m series A round but is divesting its stake over concerns about its facial recognition technology.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
